{Reference Type}: Journal Article
{Title}: Real-world safety profile of tetracyclines in children younger than 8 years old: an analysis of FAERS database and review of case report.
{Author}: Dou W;Liu X;An P;Zuo W;Zhang B;
{Journal}: Expert Opin Drug Saf
{Volume}: 0
{Issue}: 0
{Year}: 2024 May 28
{Factor}: 4.011
{DOI}: 10.1080/14740338.2024.2359615
{Abstract}: <B>UNASSIGNED: </B>The study aims to obtain the real-world safety profile of tetracyclines in children younger than 8 years old and provide reference for clinical drug applications.<BR><B>UNASSIGNED: </B>We made a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database through OpenVigil 2 and conducted a review of case reports regarding adverse drug reactions (ADRs) of tetracyclines in children younger than 8-year-old.<BR><B>UNASSIGNED: </B>FAERS analysis identified 32 ADRs of tetracyclines in children younger than 8-year-old. Respiratory, thoracic, and mediastinal disorders contained the most frequent ADRs among all system organ classes (SOCs). The top three positive signals with the highest proportional reporting ratio (PRR) were laryngeal injury, Horner's syndrome and methaemoglobinaemia. Sixteen published tetracyclines-associated cases in children younger than 8-year-old were identified in the literature, concentrating in three SOCs. Gastrointestinal disorders were the most commonly reported cases (n = 12).<BR><B>UNASSIGNED: </B>Several ADRs were newly reported only in children younger than 8-year-old in our research, including Horner's syndrome and methemoglobinemia. We recommended that the clinical practitioners should pay attention to the ADRs both in instruction and beyond the label. Take close care of children and timely intervene when the treatment is inevitable.